CN114540316B - 溶瘤病毒及其应用 - Google Patents

溶瘤病毒及其应用 Download PDF

Info

Publication number
CN114540316B
CN114540316B CN202210094869.1A CN202210094869A CN114540316B CN 114540316 B CN114540316 B CN 114540316B CN 202210094869 A CN202210094869 A CN 202210094869A CN 114540316 B CN114540316 B CN 114540316B
Authority
CN
China
Prior art keywords
ser
leu
lys
gly
asp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210094869.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN114540316A (zh
Inventor
周国庆
张凡
马良
田婷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Rongrui Pharmaceutical Technology Co ltd
Original Assignee
Shanghai Rongrui Pharmaceutical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Rongrui Pharmaceutical Technology Co ltd filed Critical Shanghai Rongrui Pharmaceutical Technology Co ltd
Priority to CN202411986426.9A priority Critical patent/CN119736261A/zh
Priority to CN202210094869.1A priority patent/CN114540316B/zh
Priority to CN202411986002.2A priority patent/CN119709649A/zh
Priority to CN202411986145.3A priority patent/CN119709651A/zh
Priority to CN202411986368.XA priority patent/CN119709652A/zh
Priority to CN202411986086.XA priority patent/CN119709650A/zh
Publication of CN114540316A publication Critical patent/CN114540316A/zh
Priority to EP23745906.0A priority patent/EP4471132A4/en
Priority to PCT/CN2023/071375 priority patent/WO2023143023A1/zh
Priority to AU2023210771A priority patent/AU2023210771A1/en
Priority to KR1020247028113A priority patent/KR20240137069A/ko
Priority to JP2024544471A priority patent/JP2025503188A/ja
Priority to CA3243385A priority patent/CA3243385A1/en
Priority to US18/785,273 priority patent/US20240424040A1/en
Application granted granted Critical
Publication of CN114540316B publication Critical patent/CN114540316B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20251—Methods of production or purification of viral material
    • C12N2760/20252—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN202210094869.1A 2022-01-26 2022-01-26 溶瘤病毒及其应用 Active CN114540316B (zh)

Priority Applications (13)

Application Number Priority Date Filing Date Title
CN202411986426.9A CN119736261A (zh) 2022-01-26 2022-01-26 溶瘤病毒及其应用
CN202210094869.1A CN114540316B (zh) 2022-01-26 2022-01-26 溶瘤病毒及其应用
CN202411986002.2A CN119709649A (zh) 2022-01-26 2022-01-26 溶瘤病毒及其应用
CN202411986145.3A CN119709651A (zh) 2022-01-26 2022-01-26 溶瘤病毒及其应用
CN202411986368.XA CN119709652A (zh) 2022-01-26 2022-01-26 溶瘤病毒及其应用
CN202411986086.XA CN119709650A (zh) 2022-01-26 2022-01-26 溶瘤病毒及其应用
EP23745906.0A EP4471132A4 (en) 2022-01-26 2023-01-09 ONCOLYTIC VIRUS AND ITS USES
PCT/CN2023/071375 WO2023143023A1 (zh) 2022-01-26 2023-01-09 溶瘤病毒及其应用
AU2023210771A AU2023210771A1 (en) 2022-01-26 2023-01-09 Oncolytic virus and use thereof
KR1020247028113A KR20240137069A (ko) 2022-01-26 2023-01-09 종양 용해 바이러스 및 이의 응용
JP2024544471A JP2025503188A (ja) 2022-01-26 2023-01-09 腫瘍溶解性ウイルス及びその用途
CA3243385A CA3243385A1 (en) 2022-01-26 2023-01-09 ONCOLYTIC VIRUS AND ITS USES
US18/785,273 US20240424040A1 (en) 2022-01-26 2024-07-26 Oncolytic virus and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210094869.1A CN114540316B (zh) 2022-01-26 2022-01-26 溶瘤病毒及其应用

Related Child Applications (5)

Application Number Title Priority Date Filing Date
CN202411986086.XA Division CN119709650A (zh) 2022-01-26 2022-01-26 溶瘤病毒及其应用
CN202411986002.2A Division CN119709649A (zh) 2022-01-26 2022-01-26 溶瘤病毒及其应用
CN202411986368.XA Division CN119709652A (zh) 2022-01-26 2022-01-26 溶瘤病毒及其应用
CN202411986145.3A Division CN119709651A (zh) 2022-01-26 2022-01-26 溶瘤病毒及其应用
CN202411986426.9A Division CN119736261A (zh) 2022-01-26 2022-01-26 溶瘤病毒及其应用

Publications (2)

Publication Number Publication Date
CN114540316A CN114540316A (zh) 2022-05-27
CN114540316B true CN114540316B (zh) 2025-01-03

Family

ID=81673943

Family Applications (6)

Application Number Title Priority Date Filing Date
CN202210094869.1A Active CN114540316B (zh) 2022-01-26 2022-01-26 溶瘤病毒及其应用
CN202411986002.2A Pending CN119709649A (zh) 2022-01-26 2022-01-26 溶瘤病毒及其应用
CN202411986086.XA Pending CN119709650A (zh) 2022-01-26 2022-01-26 溶瘤病毒及其应用
CN202411986145.3A Pending CN119709651A (zh) 2022-01-26 2022-01-26 溶瘤病毒及其应用
CN202411986368.XA Pending CN119709652A (zh) 2022-01-26 2022-01-26 溶瘤病毒及其应用
CN202411986426.9A Pending CN119736261A (zh) 2022-01-26 2022-01-26 溶瘤病毒及其应用

Family Applications After (5)

Application Number Title Priority Date Filing Date
CN202411986002.2A Pending CN119709649A (zh) 2022-01-26 2022-01-26 溶瘤病毒及其应用
CN202411986086.XA Pending CN119709650A (zh) 2022-01-26 2022-01-26 溶瘤病毒及其应用
CN202411986145.3A Pending CN119709651A (zh) 2022-01-26 2022-01-26 溶瘤病毒及其应用
CN202411986368.XA Pending CN119709652A (zh) 2022-01-26 2022-01-26 溶瘤病毒及其应用
CN202411986426.9A Pending CN119736261A (zh) 2022-01-26 2022-01-26 溶瘤病毒及其应用

Country Status (8)

Country Link
US (1) US20240424040A1 (cg-RX-API-DMAC7.html)
EP (1) EP4471132A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025503188A (cg-RX-API-DMAC7.html)
KR (1) KR20240137069A (cg-RX-API-DMAC7.html)
CN (6) CN114540316B (cg-RX-API-DMAC7.html)
AU (1) AU2023210771A1 (cg-RX-API-DMAC7.html)
CA (1) CA3243385A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023143023A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114540316B (zh) * 2022-01-26 2025-01-03 上海荣瑞医药科技有限公司 溶瘤病毒及其应用
CN117402837A (zh) * 2022-07-14 2024-01-16 上海荣瑞医药科技有限公司 一种重组溶瘤病毒及其应用
CN117402836A (zh) * 2022-07-14 2024-01-16 上海荣瑞医药科技有限公司 重组溶瘤病毒及其应用
CN116350759A (zh) * 2023-03-30 2023-06-30 上海荣瑞医药科技有限公司 溶瘤病毒疫苗和免疫细胞联合治疗肿瘤的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109312366A (zh) * 2016-05-19 2019-02-05 慕尼黑工业大学附属伊萨右岸医院 用于肿瘤溶瘤治疗的vsv/ndv杂合病毒
CN110305198A (zh) * 2018-03-27 2019-10-08 苏州奥特铭医药科技有限公司 一种溶瘤棒状病毒减毒株及其在肿瘤治疗中的应用
CN111286493A (zh) * 2020-05-12 2020-06-16 上海荣瑞医药科技有限公司 一种溶瘤病毒疫苗及其与免疫细胞联合治疗肿瘤的药物
CN111467489A (zh) * 2020-05-12 2020-07-31 上海荣瑞医药科技有限公司 一种治疗肿瘤的药物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1769433B (zh) * 2004-11-04 2011-03-16 张庆勇 重组水疱性口炎病毒及其应用
WO2009082664A2 (en) * 2007-12-21 2009-07-02 Wyeth Genetically modified attenuated vesicular stomatitis virus, compositions and methods of use thereof
DE102008050860A1 (de) * 2008-10-08 2010-04-15 Dorothee Von Laer LCMV-GP-VSV-Pseudotypvektoren und tumorinfiltrierende Virenproduzentenzellen zur Therapie von Tumoren
AR097648A1 (es) 2013-09-13 2016-04-06 Amgen Inc Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
CN105087645A (zh) * 2015-08-04 2015-11-25 上海交通大学 M蛋白三氨基酸位点突变的猪用vsv病毒载体构建和应用
CN110819657B (zh) * 2018-08-10 2021-11-19 睿丰康生物医药科技(浙江)有限公司 一种减毒棒状病毒的制备方法及应用
TW202600150A (zh) * 2019-01-25 2026-01-01 德商百靈佳殷格翰國際股份有限公司 編碼ccl21之重組棒狀病毒
CN113832114A (zh) * 2020-06-23 2021-12-24 南京大学 一种新型溶瘤腺病毒EM/VSV-G Ad5-P及其在制备抗肿瘤药物中的应用
CN114540316B (zh) * 2022-01-26 2025-01-03 上海荣瑞医药科技有限公司 溶瘤病毒及其应用
CN117402837A (zh) * 2022-07-14 2024-01-16 上海荣瑞医药科技有限公司 一种重组溶瘤病毒及其应用
CN117402836A (zh) * 2022-07-14 2024-01-16 上海荣瑞医药科技有限公司 重组溶瘤病毒及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109312366A (zh) * 2016-05-19 2019-02-05 慕尼黑工业大学附属伊萨右岸医院 用于肿瘤溶瘤治疗的vsv/ndv杂合病毒
CN110305198A (zh) * 2018-03-27 2019-10-08 苏州奥特铭医药科技有限公司 一种溶瘤棒状病毒减毒株及其在肿瘤治疗中的应用
CN111286493A (zh) * 2020-05-12 2020-06-16 上海荣瑞医药科技有限公司 一种溶瘤病毒疫苗及其与免疫细胞联合治疗肿瘤的药物
CN111467489A (zh) * 2020-05-12 2020-07-31 上海荣瑞医药科技有限公司 一种治疗肿瘤的药物

Also Published As

Publication number Publication date
CN119709650A (zh) 2025-03-28
EP4471132A1 (en) 2024-12-04
WO2023143023A1 (zh) 2023-08-03
CN119709652A (zh) 2025-03-28
EP4471132A4 (en) 2026-02-25
US20240424040A1 (en) 2024-12-26
AU2023210771A1 (en) 2024-08-15
CN114540316A (zh) 2022-05-27
KR20240137069A (ko) 2024-09-19
CN119709651A (zh) 2025-03-28
CN119736261A (zh) 2025-04-01
JP2025503188A (ja) 2025-01-30
CA3243385A1 (en) 2025-06-17
CN119709649A (zh) 2025-03-28

Similar Documents

Publication Publication Date Title
JP7468958B2 (ja) 腫瘍溶解性ウイルスワクチン及びそれと免疫細胞の併用による腫瘍治療薬物
US20240424040A1 (en) Oncolytic virus and use thereof
JP2025503188A5 (cg-RX-API-DMAC7.html)
EP4545634A1 (en) Recombinant oncolytic virus and use thereof
AU2019254948B2 (en) Coxsackie virus B for treating tumors
WO2022135357A1 (en) A hIL7/hCCL19 DOUBLE GENE RECOMBINANT ONCOLYTIC VIRUS AND ITS PREPARATION METHOD AND USE
US20220033445A1 (en) Method for producing an antitumoral arenavirus as well as arenavirus mutants
CN109568350B (zh) 一种用于治疗肿瘤的柯萨奇病毒
CN113939304B (zh) M1病毒变异体及其应用
CN115612674B (zh) 一种溶瘤病毒及其用途
AU2018320550B2 (en) Echovirus for treating tumor
HK40105653A (en) Oncolytic virus and use thereof
JP2023526905A (ja) マイクロrnaで調節及び制御可能な単離された組換え腫瘍溶解性ポックスウイルス及びその使用
CA3262126A1 (en) Recombinant oncolytic virus and use thereof
HK40061716B (en) M1 virus mutant and use thereof
TW202200787A (zh) M1病毒變異體及其應用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: Zhou Guoqing

Inventor after: Zhang Fan

Inventor after: Ma Liang

Inventor after: Tian Ting

Inventor before: Zhou Guoqing

Inventor before: Zhang Fan

GR01 Patent grant
GR01 Patent grant